Company intelligence / Profile preview
XL-protein
Freising/Weihenstephan, Bavaria, Germanyxl-protein.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Commercial
01
Overview
XL-protein develops biopharmaceuticals using its proprietary PASylation® technology to extend plasma half-life of therapeutic proteins. This enables less frequent dosing and improved tolerability. The company has demonstrated efficient production of hyperactive PASylated DNase I with extended half-life and has an immunosuppressive PASylated antibody fragment supported by the Bavarian Research Foundation for cardiac xenotransplantation. Most results are preclinical, with some programs advancing toward early clinical phases through spin-outs or partnerships.
- Therapeutic areas
- OtherCardiovascular
- Modalities
- Recombinant proteinProtein (PASylated proteins)Polymer-drug conjugate therapy (PASylation as a polymer alternative to PEGylation)Biologic
- Industry
- Biotech
02
Drug pipeline
22 assets21 more assets in the full pipeline.
Request access →03
Partnerships
Rentschler Biopharma (production collaboration)multiple undisclosed international pharma/biotech partners at various levels
Beyond the preview
Go deeper on XL-protein.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XL-protein.